The Genome Valley region has played a pivotal role in fostering the life science industry and the state government has always supported its growth
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
The transaction as well as the open offer is expected to be completed by June this year.
According to the state government, it will also provide support to special projects such as preclinical testing, genome sequencing in the private sector, private sector BSL-3 lab-vaccine development and manufacturing and testing and certification laboratories
According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic
The companies plan to use the proceeds to retire debt and expand operations
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
The entire integration and transition of the brands is expected to be completed by March 2022
Key takeaways of Q3FY22 quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
